Peptides DB
Research-centric peptide and protocol reference hub
Study 10 of 11Efpeglenatide literatureAnnals of the rheumatic diseases · Animal study2026

Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody-driven mouse model of systemic sclerosis.

FcRn blockade with efgartigimod shows promise in reducing fibrosis and inflammation in a mouse model of systemic sclerosis, but further clinical studies are needed to confirm these effects in humans.

Read at Annals of the rheumatic diseasesAdd to compare

Where it sits

this study against the rest of the efpeglenatide corpus
1
Preclinical · this one
7
Observational
0
Open-label
1
Randomised
2
Reviews

Summary and findings

The study evaluated the effects of murinised efgartigimod (mEfgartigimod) on autoimmunity-driven fibrosis in a mouse model of systemic sclerosis (SSc). Both prophylactic and therapeutic mEfgartigimod treatments were assessed for their impact on fibrosis and inflammatory signaling pathways. The findings suggest potential benefits of FcRn blockade in reducing fibrosis and inflammation.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Annals of the rheumatic diseases supplied them

<h4>Objectives</h4>Several autoantibodies promote inflammation and fibrosis in systemic sclerosis (SSc). Efgartigimod, engineered to block the neonatal fragment crystallisable (Fc) receptor (FcRn) and reduce immunoglobulin G (IgG) autoantibody levels, is approved for autoantibody-driven generalised myasthenia gravis and chronic inflammatory demyelinating neuropathy.<h4>Methods</h4>FcRn blockade with murinised efgartigimod (mEfgartigimod) and an FcRn-blocking IgG1 Fc fragment was evaluated in the topoisomerase-I (TopoI)-induced mouse model of autoimmunity-driven fibrosis. Effects were assessed by immunoglobulin levels, biochemical and histological fibrosis readouts, Olink analyses, RNA sequencing (RNA-Seq), and imaging mass cytometry (IMC).<h4>Results</h4>Both prophylactic and therapeutic mEfgartigimod ameliorated dermal and pulmonary fibrosis in TopoI mice, comparably to nintedanib. Bulk RNA-Seq analysis demonstrated FcRn blockade with mEfgartigimod downregulated inflammatory, autoimmune, and fibrotic signalling pathways, with reduced expression of Ccl chemokines, tumour necrosis factor superfamily cytokines, and type I interferon signalling components. IMC showed reduced accumulation of myofibroblasts, classically activated macrophages, dendritic cells, and T cells upon FcRn blockade. Single‑nucleus RNA-Seq revealed altered fibroblast-macrophage crosstalk, with decreases in myofibroblasts, inflammatory and neutrophil-like macrophages, and T cells with cell-type-specific transcriptional effects associated with reversal of profibrotic/inflammatory transcriptional programs. Consistent with these cellular changes, the circulating levels of Il1β and several chemokines were downregulated upon treatment, whereas antifibrotic mediators, such as Fgf21 and soluble Pd-l2, were upregulated.<h4>Conclusion</h4>These findings highlight that FcRn blockers such as efgartigimod may have potential to simultaneously target autoimmune, inflammatory, and fibrotic features of SSc and highlight the potential of autoantibody-reducing therapies as disease-modifying approaches in SSc. A randomised, controlled phase 2 trial with efgartigimod in SSc is currently ongoing.

Background

This paper addresses the role of autoantibodies in promoting inflammation and fibrosis in systemic sclerosis (SSc). Previous research has indicated that targeting the neonatal Fc receptor (FcRn) can reduce immunoglobulin G (IgG) autoantibody levels. The study is significant as it explores the potential of FcRn blockade to ameliorate multiple disease features in SSc.

Methods

The study utilized a topoisomerase-I (TopoI)-induced mouse model to evaluate the effects of FcRn blockade with mEfgartigimod. The primary outcome measures included immunoglobulin levels, biochemical and histological fibrosis readouts, and RNA sequencing. Specific details regarding sample size and duration were not reported in the abstract.

Results

Both prophylactic and therapeutic mEfgartigimod ameliorated dermal and pulmonary fibrosis in TopoI mice, comparably to nintedanib. The study reported downregulation of inflammatory, autoimmune, and fibrotic signalling pathways, but specific numeric findings were not detailed.

Interpretation

The findings suggest that FcRn blockade may have a multifaceted impact on autoimmune and fibrotic processes in SSc, aligning with previous literature on the role of autoantibodies in disease progression. However, the clinical significance of the observed effects remains uncertain, particularly given the reliance on a mouse model and the absence of human data.

Key findings

  • FcRn blockade with mEfgartigimod downregulated inflammatory, autoimmune, and fibrotic signalling pathways.
  • Reduced expression of Ccl chemokines, tumour necrosis factor superfamily cytokines, and type I interferon signalling components.
  • Decreased accumulation of myofibroblasts, classically activated macrophages, dendritic cells, and T cells upon FcRn blockade.

Limitations

  • Study based on a mouse model, limiting human applicability.
  • Preliminary findings require validation in human trials.
  • Not reported in abstract.

Elsewhere in the Efpeglenatide corpus

BDisease burden among patients with generalized myasthenia gravis in the United States receiving standard of care therapy: the patient perspective.Current medical research and opinion · 2026 · n=157 · gMG severity was associated with severity of health-related quality of life impairment (coefficient 0.103 [95% CI 0.043, 0.191]).HumanASafety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis.Brain and behavior · 2023 · n=480 · MD = -4.59 for QMG scores, 95% CI: -6.24 to -2.94, p < 0.00001.reviewBA Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast-Acting Treatment for Impeding Crisis of MuSK-MG.Immunity, inflammation and disease · 2023 · n=1 · QMG score improved from 31 to 23 after the first efgartigimod infusion.HumanBImmune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series.Experimental and therapeutic medicine · 2026 · n=6 · Median age 70.5 years (range, 63-83 years).HumanBPerioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series.Journal of neuroimmunology · 2026 · n=6 · Not reported in abstract.HumanBDurable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.Platelets · 2026 · n=1 · Not reported in abstract.Human